Chinese Expert Consensus on Antithrombotic Drug Management for Patients with Cardiovascular Diseases Undergoing Prostate Biopsy
National Clinical Research Center for Cardiovascular Diseases-Urology Cardiovascular Comorbidity
Zhang Ning
Abstract：Prostate biopsy is a critical method for distinguishing between benign and malignant prostate tumors.As the population ages and the incidence of cardiovascular diseases gradually increases,patients scheduled for pros-tate biopsy often receive antithrombotic treatment due to concurrent cardiovascular conditions.During the periopera-tive period,the continuation of antithrombotic medications raises the risk of bleeding,whereas their discontinuation may lead to thrombosis and potentially exacerbate cardiovascular diseases.The establishment of standardized manage-ment protocols for antithrombotic drugs in these patients is an urgent issue that requires resolution.The consensus is reached through multidisciplinary discussions among relevant experts,combined with the latest domestic and interna-tional literature and guideline evidence.The objective is to clarify the timing of prostate biopsy,balance the risks of perioperative bleeding and thrombosis,formulate standardized management strategies for antithrombotic medica-tions,and develop clinical management plans for postoperative bleeding,thereby providing a foundation and guidance for clinical diagnosis and treatment.
Keywords：Prostate BiopsyCardiovascular DiseaseAntithrombotic drugConsensus
Publication Date：2024-10-05
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：10( 289-298 )